Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eupraxia Pharmaceuticals Inc. (EPRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market and Toronto Stock Exchange. Eupraxia files under the multijurisdictional disclosure system, using Form 40-F for annual reporting and Form 6-K for current reports under the Securities Exchange Act of 1934.
Recent Form 6-K submissions for Eupraxia include press releases, consolidated financial statements, and management’s discussion and analysis for specific periods. For example, filings incorporate interim financial statements and MD&A for quarters ended June 30 and September 30, as well as press releases summarizing clinical data from the RESOLVE trial, financial results, and details of public offerings of common shares. Some 6-Ks also attach material change reports, underwriting agreements, and certifications of interim filings by senior officers.
For investors analyzing EPRX, these filings are key sources of information on clinical development, financial position, and capital markets activity. They describe the status of EP-104GI and EP-104IAR, outline risk factors and forward-looking statements, and explain how proceeds from offerings are intended to support clinical trials, regulatory submissions, manufacturing scale-up, and pipeline expansion. They also discuss operational considerations such as reliance on third-party manufacturers and contract research organizations, and potential impacts of tariffs on clinical supplies.
On Stock Titan, Eupraxia’s filings are updated as new documents are posted to EDGAR, and AI-powered summaries help interpret lengthy exhibits. Users can quickly see which 6-Ks contain financial statements, which include clinical data press releases, and how each filing fits into the broader narrative of EPRX’s development programs and funding strategy.
EUPRAXIA PHARMACEUTICALS INC. submitted a Form 6-K reporting its principal executive office address in Victoria, British Columbia, and indicated it files annual reports under Form 40-F. The report includes an exhibit: Exhibit 99.1, a press release dated September 22, 2025. The document is signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025. The filing appears to be a routine disclosure providing company contact details, the chosen annual-reporting form and a referenced press release.